Summit Therapeutics Inc.
SMMT
Classement en actions
#1661
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Prix de l'action
$16.14
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$12.87B
Changement (1 jour)
3.65%
Changement (1 an)
-13.88%
Pays
US
Échange Summit Therapeutics Inc. (SMMT)
Catégorie
Healthcare
Ratio P/S pour Summit Therapeutics Inc. (SMMT)
Ratio P/S au October 2026 TTM : 0.00
Selon les derniers rapports financiers et le cours de l'action de Summit Therapeutics Inc., le ratio cours/ventes actuel (TTM) est 0.00. À la fin de 2023, le ratio P/S était de 0.00.
Historique du ratio P/S pour Summit Therapeutics Inc. de 2004 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | 1.17K | 750.59% |
| 2021 | 137.16 | -63.90% |
| 2020 | 379.96 | 488.81% |
| 2019 | 64.53 | 79.48% |
| 2018 | 35.95 | -79.79% |
| 2017 | 177.88 | -39.71% |
| 2016 | 295.05 | 149.79% |
| 2015 | 118.12 | 47.03% |
| 2014 | 80.33 | 126.64% |
| 2013 | 35.45 | 30.78% |
| 2012 | 27.10 | -86.53% |
| 2011 | 201.22 | -85.80% |
| 2010 | 1.42K | 0.83% |
| 2009 | 1.41K | 3,348.90% |
| 2008 | 40.74 | -56.22% |
| 2007 | 93.07 | -50.79% |
| 2006 | 189.15 | -68.30% |
| 2005 | 596.76 | -98.98% |
| 2004 | 58.27K | 0.00% |
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
